<DOC>
	<DOC>NCT00235560</DOC>
	<brief_summary>These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.</brief_summary>
	<brief_title>Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients</brief_title>
	<detailed_description>Evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age &gt; 60 y. Informed consent de novo or secondary LAM(CML excluded) not elligible for intensive chemotherapy. Previously untreated Renal impairment (serum creatinin &gt;2N) Hepatic impairment (TGO ou TGP &gt; 5N), une cholestase (Phosphatases Alcalines or gammaGT &gt; 5N),bilirubin &gt; 3N Blast crisis CML Acute Promyelocytic Leukemia</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>AML</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>Elderly</keyword>
	<keyword>Elderly patients not eligible for intensive chemotherapy</keyword>
</DOC>